Last checked at 12 Oct 2018 16:43
12 October 2018
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on the 9 and 10 October 2018 it purchased 100,000 and 180,790 Ordinary Shares of 1p, respectively, in the capital of the Company ("Ordinary Shares") at 3.66p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 61,132,777 equivalent to 20.71% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes Investment Management and the Company, he now has an interest in 61,132,777 Ordinary Shares of the Company representing 20.71% of the issued share capital of the Company.
The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) | Name: | Martin Diggle | ||||||
| Reason for the notification | |||||||
a) | Position/status: | Non-Executive Director | ||||||
b) | Initial notification/Amendment: | Initial Notification | ||||||
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name: | Proteome Sciences Plc | ||||||
b) | LEI: | 213800Q62ICXANKU2986 | ||||||
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 1p nominal value GB0003104196 | ||||||
b) | Nature of the transaction: | Purchase of Ordinary Shares | ||||||
c) | Price(s) and volume(s): |
| ||||||
d) | Aggregated information: · Aggregated volume: · Price: | Single transaction as in 4 c) above
| ||||||
e) | Date of the transaction: | 9 October 2018 and 10 October 2018 respectively | ||||||
f) | Place of the transaction: | London Stock Exchange, AIM (XLON) | ||||||
For further information:
Proteome Sciences plc | |
Dr Jeremy Haigh, Chief Executive Officer | Tel: +44 (0)20 7043 2116 |
Dr Ian Pike, Chief Scientific Officer Richard Dennis, Chief Commercial Officer | |
finnCap Limited (Nominated Adviser & Broker) | |
Geoff Nash/Hannah Boros (Corporate Finance) Tim Redfern (Broking) | Tel: +44 (0)20 7220 0500
|
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.